Literature DB >> 22851054

Kinetics and stereochemistry of hydrolysis of an N-(phenylacetyl)-α-hydroxyglycine ester catalyzed by serine β-lactamases and DD-peptidases.

Ryan B Pelto1, R F Pratt.   

Abstract

The α-hydroxydepsipeptide 3-carboxyphenyl N-(phenylacetyl)-α-hydroxyglycinate (5) is a quite effective substrate of serine β-lactamases and low molecular mass DD-peptidases. The class C P99 and ampC β-lactamases catalyze the hydrolysis of both enantiomers of 5, although they show a strong preference for one of them. The class A TEM-2 and class D OXA-1 β-lactamases and the Streptomyces R61 and Actinomadura R39 DD-peptidases catalyze hydrolysis of only one enantiomer of at any significant rate. Experiments show that all of the above enzymes strongly prefer the same enantiomer, a surprising result since β-lactamases usually prefer L(S) enantiomers and DD-peptidases D(R). Product analysis, employing peptidylglycine α-amidating lyase, showed that the preferred enantiomer is D(R). Thus, it is the β-lactamases that have switched preference rather than the DD-peptidases. Molecular modeling of the P99 β-lactamase active site suggests that the α-hydroxyl 5 of may interact with conserved Asn and Lys residues. Both α-hydroxy and α-amido substituents on a glycine ester substrate can therefore enhance its productive interaction with the β-lactamase active site, although their effects are not additive; this may also be true for inhibitors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22851054      PMCID: PMC3684201          DOI: 10.1039/c2ob25585e

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  24 in total

1.  7-alkylidenecephalosporin esters as inhibitors of human leukocyte elastase.

Authors:  J D Buynak; A S Rao; G P Ford; C Carver; G Adam; B Geng; B Bachmann; S Shobassy; S Lackey
Journal:  J Med Chem       Date:  1997-10-10       Impact factor: 7.446

2.  The diversity of the catalytic properties of class A beta-lactamases.

Authors:  A Matagne; A M Misselyn-Bauduin; B Joris; T Erpicum; B Granier; J M Frère
Journal:  Biochem J       Date:  1990-01-01       Impact factor: 3.857

3.  Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase.

Authors:  P Kuzmic
Journal:  Anal Biochem       Date:  1996-06-01       Impact factor: 3.365

4.  Effect of the 3'-leaving group on turnover of cephem antibiotics by a class C beta-lactamase.

Authors:  L J Mazzella; R F Pratt
Journal:  Biochem J       Date:  1989-04-01       Impact factor: 3.857

5.  Interactions between active-site-serine beta-lactamases and compounds bearing a methoxy side chain on the alpha-face of the beta-lactam ring: kinetic and molecular modelling studies.

Authors:  A Matagne; J Lamotte-Brasseur; G Dive; J R Knox; J M Frère
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

6.  The synthesis and antibacterial activity of some beta-lactamase stable 6 alpha-(hydroxymethyl)penicillins.

Authors:  R A Dixon; R A Edmondson; K D Hardy; P H Milner
Journal:  J Antibiot (Tokyo)       Date:  1984-12       Impact factor: 2.649

7.  On the importance of a methyl group in beta-lactamase evolution: free energy profiles and molecular modeling.

Authors:  N J Bernstein; R F Pratt
Journal:  Biochemistry       Date:  1999-08-10       Impact factor: 3.162

8.  A survey of the kinetic parameters of class C beta-lactamases. Cephalosporins and other beta-lactam compounds.

Authors:  M Galleni; G Amicosante; J M Frère
Journal:  Biochem J       Date:  1988-10-01       Impact factor: 3.857

9.  Antibacterial activity and beta-lactamase stability of temocillin.

Authors:  K Jules; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

10.  Determination of the absolute configuration of alpha-hydroxyglycine derivatives by enzymatic conversion and chiral high-performance liquid chromatography.

Authors:  J K McIninch; F Geiser; K B Prickett; S W May
Journal:  J Chromatogr A       Date:  1998-12-18       Impact factor: 4.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.